The share prices of Bristol-Myers Squibb Co's were up by 2.6% higher even in the thin Frankfurt market. There were reports that its experimental drug ipilimumab significantly helped increase survival rates in patients with skin cancer.

But share prices of Roche Holding AG and Novartis AG did not find many takers. These Companies have the largest number of drugs for the world's top cancer meeting in Chicago. But investors are not very excited with these Companies and their share prices remain largely unaffected. 

However, the success of Bristol's ipilimumab is expected to increase the valuations for the Company significantly in the coming days. Experts feel that the drug has the potential to generate more than $1 billion-plus sales. Leading brokers have already increased the ratings of Bristol.

Roche is also reporting the results of a high-profile clinical study at the American Society of Clinical Oncology (ASCO) meeting in Chicago. It will reveal the data for drug Avastin used in ovarian cancer.

But experts claim that the results are not very surprising and though positive, did not offer anything extraordinary. Stock market experts also feel that the demand for Roche's shares is not expected to grow significantly. The share price of Roche was down 0.9% at 1040 GMT in line with the expectations of the European healthcare sector.